Amylyx Pharmaceuticals, Inc. (AMLX) — Analyst outlook / Analyst consensus target is. Based on 11 analyst ratings, the consensus is bullish — 10 Buy, 1 Hold.
The consensus price target is $22.00 (low: $19.00, high: $28.00), representing an upside of 30% from the current price $16.92.
Analysts estimate Earnings Per Share (EPS) of $-4.33 and revenue of $0.09B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-4.43 vs est $-4.33 (missed -2.3%). 2025: actual $-1.53 vs est $-1.55 (beat +1.4%). Analyst accuracy: 98%.
AMLX Stock — 12-Month Price Forecast
$22.00
▲ +30.02% Upside
Average Price Target
Based on 11 Wall Street analysts offering 12-month price targets for Amylyx Pharmaceuticals, Inc., the average price target is $22.00, with a high forecast of $28.00, and a low forecast of $19.00.
The average price target represents a +30.02% change from the last price of $16.92.
Highest Price Target
$28.00
Average Price Target
$22.00
Lowest Price Target
$19.00
AMLX Analyst Ratings
Buy
Based on 11 analysts giving stock ratings to Amylyx Pharmaceuticals, Inc. in the past 3 months
EPS Estimates — AMLX
98%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$4.43
vs Est –$4.33
▼ 2.2% off
2025
Actual –$1.53
vs Est –$1.55
▲ 1.4% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — AMLX
99%
Analyst Accuracy
Accurate
1 year compared
Actual vs Estimate
2024
Actual $0.087B
vs Est $0.088B
▼ 0.8% off
Revenue Trend
Revenue has declined over the period shown. Analysts expect stable revenue going forward.
